Mark Feinberg is President and CEO of the International AIDS Vaccine Initiative (IAVI) where he leads a global team working to advance the development of vaccines and other biomedical innovations to protect against infection with HIV, TB and other infectious diseases that disproportionately impact low income countries.

Prior to joining IAVI in late 2015, Mark served as Chief Public Health and Science Officer with Merck Vaccines. In this role, he helped advance the development and global availability of vaccines against rotavirus, human papillomavirus and other infectious diseases. He also led a range of research initiatives to address unmet health needs in low income countries including the establishment of the MSD-Wellcome Trust Hilleman Laboratories and the coordination of a private-public partnership to expedite Ebola vaccine development. Previously, he spent more than 20 years exploring HIV/AIDS pathogenesis, treatment and prevention research and the biology of emerging diseases in both academia and government.

Mark holds an MD and a PhD from Stanford University, and BA degree from the University of Pennsylvania. He pursued post-graduate medical training at Brigham and Women’s Hospital and postdoctoral fellowship training in the laboratory of Dr. David Baltimore at the Whitehead Institute. He has previously served as a faculty member at the University of California, San Francisco and the Emory University School of Medicine, and as a Medical Officer in the Office of AIDS Research at the National Institutes of Health.